Protocol from Anodyne Headache and Pain Care in Texas gave 0.3 mg – 0.4 mg/kg ketamine divided into 3 deltoid IM shots separated by 15 minutes for headache and neuropathic pain. A remarkably successful ketamine IV treatment for depression gave 0.5 mg/kg iv over 1oo minutes. Could they be different flavours of the same thing?
INTRAMUSCULAR (IM) KETAMINE FOR TREATING MIGRAINE AND NEUROPATHIC PAIN IN THE CLINIC
John Claude Krusz, PhD, MD, Stephanie Hall, BS, MPH, Jane Cagle, LVN
Anodyne Headache and PainCare, Dallas, Texas, United States, 75231 (www.anodyneheadachepain.com)
Poster online at
- 17 cases
- 0.3-0.4 mg per kilogram of ketamine.
- “dose was injected in three to four portions intramuscularly, with 10 to 15 minutes between injections.”
- “No patient fell asleep during treatment, nor were there any instances of hallucinations or emergence “delirium. 4 patients described a sense of exhilaration or “spaciness” transiently after ketamine was given.”
- “Some patients (n=5) received more than 1 set of IM ketamine injections. One patient received 11 sets of injections for frequent refractory migraines.”
Protocol for depression:
Serial infusions of low-dose ketamine for major depression
Keith G Rasmussen et al
J Psychopharmacol May 2013 vol. 27 no. 5 444-450
- 10 cases
- twice weekly ketamine infusions of 0.5 mg/kg administered over 100 min
- given until either remission was achieved or four infusions were given.
- “Five of 10 patients achieved remission status…. Two of the remitting patients sustained their improvement throughout the four week follow-up period.”
- No increase in hypomania scores [Young Mania Rating Scale (YMRS)]
- No increase psychosis [Brief Psychiatric Rating Scale (BPRS)]
Comment – I have been giving 10 mg ketamine IM deltoid x2 for chronic pain and x3 for chronic pain and significant depression. If on high dose opioids, elderly, or small, dose is reduce to half that. It will reduce pain by 2-3 points for 3 days and significantly improve mood. Many will say the pain comes back up the 3rd day but they don’t care because their mood is still buoyed. Any severely depressed patient is given ketamine, given that it has been shown to prevent suicide:
Int J Neuropsychopharmacol. 2011 Sep;14(8):1127-31.
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department.
Larkin GL, Beautrais AL
- suicidal emerg patients
- 0.2 mg/kg ketamine iv. over 1-2 min
- No suicidality even 1 week later
Major concern with IV ketamine has been the derealization syndrome where people feel alarmingly unreal and panicy – IV Midazolam has been used to treat (and is some cases prevent it). Never saw it with IM injectable because if they start feeling odd, they just elect not to have another dose.
Recent had a case with OCD (removes it for 3 days as well.
Rodriguez, Carolyn I., et al.
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: Proof-of-concept.
Neuropsychopharmacology 38.12 (2013): 2475-2483.
Rodriguez, Carolyn I., et al.
Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder.
The Journal of clinical psychiatry 72.4 (2011): 567-569.
She was better on 1 dose treatment but felt unsettled on 2 doses so elected to not have anymore – OCD had settled some and was not depressed.
I found out one subject on ketamine had a delusional state (thought she ran someone over) but I believe it predated the ketamine.
New insights into enhancing morphine analgesia: from glia to pharmacokinetics.” (2014).
– a rat model for ketamine use came up with this observation: “When acute ketamine was administered to rats under chronic morphine treatment, the brain concentrations of morphine, ketamine and norketamine were increased compared with the situation where either morphine treatment or acute ketamine were administered alone. There sults indicate a potentially beneficial pharmacokinetic interaction between the two drugs…Ketamine, a drug used for the treatment of opioid tolerance in cancer patients, may undergo previously unrecognized beneficial pharmacokinetic interactions with morphine.”